Literature DB >> 29862157

New onset hyperglycemia attributed to renal cell carcinoma.

Jonathan Gapp1, Muhammad Fazeel Anwar1, Jai Parekh1, Timothy Griffin2.   

Abstract

A 61-year-old male was admitted from the outpatient setting for treatment of severe hyperglycemia. Five months earlier, his hemoglobin A1c had been 5 mmol/mol. At presentation, hemoglobin A1c was 11.3 mmol/mol and he required insulin therapy at discharge. Later magnetic resonance imaging (MRI) identified bilateral renal masses, previously seen on ultrasound during workup for chronic kidney disease, as being suspicious for renal cell carcinoma (RCC). He underwent partial nephrectomy and cryoablation with pathology showing papillary type RCC. Hyperglycemia resolved after resection and insulin therapy was discontinued, requiring only an oral hypoglycemic. Hyperglycemia as a paraneoplastic syndrome related to RCC is rare. The cause of this acute hyperglycemia is not understood, though previously suggested mechanisms include ectopic glucagon production, autoimmune causes and interleukin-6 (IL-6) mediated pathways. Severe, new-onset hyperglycemia in the absence of common causes and with a renal mass on imaging may represent an uncommon paraneoplastic syndrome secondary to RCC.

Entities:  

Keywords:  Hyperglycemia; malignancy; paraneoplastic syndrome; renal cell carcinoma

Year:  2018        PMID: 29862157      PMCID: PMC5982622          DOI: 10.5582/irdr.2018.01034

Source DB:  PubMed          Journal:  Intractable Rare Dis Res        ISSN: 2186-3644


  13 in total

1.  Uncontrollable diabetes mellitus: a rare paraneoplastic manifestation of renal cell carcinoma.

Authors:  P R Callewaert; H Van Poppel; D Vanderschueren; L Baert
Journal:  Nephrol Dial Transplant       Date:  1999-09       Impact factor: 5.992

2.  Renal cell carcinoma presenting with hyperglycaemia.

Authors:  Chloe P Macaulay; J J Pati; T W Carr; A Bishop
Journal:  BJU Int       Date:  2002-05       Impact factor: 5.588

3.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

4.  New-onset insulinopenic diabetes mellitus in a patient with an incidentally discovered renal cell carcinoma.

Authors:  Alan N Elias
Journal:  Am J Med       Date:  2005-09       Impact factor: 4.965

5.  Inhibition of insulin secretion from rat islets of Langerhans by interleukin-6. An effect distinct from that of interleukin-1.

Authors:  C Southern; D Schulster; I C Green
Journal:  Biochem J       Date:  1990-11-15       Impact factor: 3.857

Review 6.  Hyperglycemia as a paraneoplastic endocrinopathy in renal cell carcinoma: a case report and review of the literature.

Authors:  B A Jobe; M H Bierman; F J Mezzacappa
Journal:  Nebr Med J       Date:  1993-11

7.  Hyperglycemia associated with renal cell carcinoma.

Authors:  N Palgon; F Greenstein; A D Novetsky; S M Lichter; Y Rosen
Journal:  Urology       Date:  1986-12       Impact factor: 2.649

8.  Circulating interleukin 6 concentrations and insulin resistance in patients with cancer.

Authors:  T Makino; Y Noguchi; T Yoshikawa; C Doi; K Nomura
Journal:  Br J Surg       Date:  1998-12       Impact factor: 6.939

9.  Renal cell cancer stage migration: analysis of the National Cancer Data Base.

Authors:  Christopher J Kane; Katherine Mallin; Jamie Ritchey; Matthew R Cooperberg; Peter R Carroll
Journal:  Cancer       Date:  2008-07-01       Impact factor: 6.860

10.  Insulin and glucagon secretion by renal adenocarcinoma.

Authors:  K Pavelić; M Popović
Journal:  Cancer       Date:  1981-07-01       Impact factor: 6.860

View more
  1 in total

1.  Renal Cell Carcinoma-Associated Diabetes Mellitus Due to Paraneoplastic Syndrome in Maintenance Hemodialysis: A Case Report.

Authors:  Yusuke Yoshimura; Tatsuya Suwabe; Daisuke Ikuma; Yuki Oba; Masayuki Yamanouchi; Akinari Sekine; Hiroki Mizuno; Eiko Hasegawa; Junichi Hoshino; Kei Kono; Keiichi Kinowaki; Kenichi Ohashi; Naoki Sawa; Yoshifumi Ubara
Journal:  Kidney Med       Date:  2022-04-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.